PTO/SB/08B (07-05)

		1 D 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	U.S. Patent	and Trademark Office; U.S. DEPARTMENT OF COM of Information unless it contains a valid OMB control	MERCE
	,		re required to respond to a conection	Complete if Known	10000
Substitute for	r torm 1449	9/210	Application Number	09/899,026	
INFOR	RMAT	ION DISCLOSURE	Filing Date	July 6, 2001	
STATI	EMEN	NT BY APPLICANT	First Named Inventor	Stamm	
			Art Unit	1615	
· (Use as m	eny sheets as necessary)	Examiner Name	Sheikh	
Sheet 1		of 4	Attomey Docket Number	224407	
05					
			ENT LITERATURE DOC		
Aminer Initials*	Cite No.1	the item (book, magazine, jo	in CAPITAL LETTERS), title numal, serial, symposium, cat s), publisher, city and/or coun	of the article (when appropriate), title of talog, etc.), date, page(s), volume-issue try where published.	T ²
	1	Laboratoires Fournier S.A. of Test Conditions Development	document entitled "Fenofibr nt Studies, Dissolution Tes	rate Tablets 54-160 mg Dissolution t Specification Recommendations"	
]	2	"Second Amended Answer, A in Abbott Laboratories et al v.	ffirmative Defenses, and Co Teva Pharmaceuticals USA	unterclaims" filed by Teva on 7-29-2005 , Inc., DE, CA No. 02-1512.	
	3			on 9-23-2005 in Abbott Delaware, CA No. 03-120-KAJ.	
	4			cy et al on 9-23-2005 in In Re Delaware, CA No. 05-340.	
* 1	5			. et al on 9-23-2005 in In Re Delaware, CA No. 05-340.	
	6			lo. 30 et al on 9-23-2005 in In Delaware, CA No. 05-340.	
	7			esale Drug Co. et al, on 10-3-2005 Delaware, CA No. 05-340.	
	8			" filed by Impax on 8-6-2003 in Delaware, CA No. 03-120-KAJ.	

	1		
Examiner Signature	inea of Sheat	Date Considered	12/09/05

"Amended Answer" filed by Impax on 1-4-2005 in Abbott Laboratories et al v.

"Reply Memorandum" filed by Impax on 2-25-2005 in Abbott Laboratories et al

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.

v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

		_				U.S. Patent	and Trademark Office: U.S. DEPARTMENT OF COM	MERCE number
				ction Ac	t or 1995, no persons an	e required to respond to a conscion	Complete if Known	
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid QMB or Complete if Known Application Number 09/899,026 Filling Date July 6, 2001 First Named Inventor Stamm Art Unit 1615 Examiner Name Sheikh Attorney Docket Number 224407 OCT 2.6 7005 NON PATENT LITERATURE DOCUMENTS Tinitials* No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-iss number(s), publisher, city and/or country where published. "Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. "Opening Brief in Support of Motion for Summary Judgment" by Teva filed on 12-23-2004 Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. "Opening Brief in Support of Motion for Summary Judgment" by Teva filed on 12-10-2004 Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. "Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. "Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. "Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott Laboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. "Opposition to European Patent No. 1 273 293 filed on 9-2-2005 by Ethypharm (French Language Document). Opposition to Israel Patent No. 130790 filed 5-4-2005 by Teva; and Remarks in Response to Opposition filed on 9-23-2005. (English Language Translations).	09/899,026							
	CLOSURE	Filing Date	July 6, 2001					
			First Named Inventor	Stamm				
						Art Unit	1615	priate), title of volume-issue T ² n Abbott 3-120-KAJ. 12-23-2004 in b. 02-1512. 10. 02-1512. 11. 02-1512. 12. 10-2004 in b. 02-1512. 13. 10-2004 in b. 02-1512.
	(U	Jse as ma	ny sheet	ts as n	ecessary)	Application Number 09/899,026 Filing Date July 6, 2001 First Named Inventor Stamm Art Unit 1615 Examiner Name Sheikh Attorney Docket Number 224407 NON PATENT LITERATURE DOCUMENTS the author (in CAPITAL LETTERS), title of the article (when appropriate), title of nagazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. In Opinion" by District Judge Jordan dated 5-6-2005 in Abbott at al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ. In Support of Motion for Summary Judgment" by Teva filed on 12-23-2004 in ries et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. In Support of Motion for Summary Judgment" by Teva filed on 12-10-2004 in ries et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Opinion" by District Judge Jordan dated 5-6-2005 in Abbott at al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. District Judge Jordan dated 5-6-2005 in Abbott at al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. European Patent No. 1 273 293 filed on 9-2-2005 by French Language Document). Strael Patent No. 130790 filed 5-4-2005 by Teva; and Remarks in poposition filed on 9-23-2005. (English Language Translations). Atherosclerosis, 110(Suppl.):S45-S48 (1994).		
Stock!	2			U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ON DISCLOSURE BY APPLICANT The late as necessary) NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (c), publisher, city and/or country where published. Idemorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion By District Judge Jordan dated 5-6-2005 in Abbott aboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Memorandum Opinion By District Judge Jordan dated 5-6-2005 by Teva; and Remarks in esponse to Opposition filed on 9-23-2005. (English Language Translations). Memorandum Opinion Filed on 9-23-2005. (English Language Translations). Memorandum Opinion Filed on 9-23-2005. (English Language Translations).				
105	_l							
25/					NON PATI	ENT LITERATURE DOC	CUMENTS	
Pram Initials	iner s*		Inclu the it	ide na tem (t	ook, magazine, jou	urnal, serial, symposium, cat	talog, etc.), date, page(s), volume-issue	T²
9	8	11	"Men Labo	nora rato	ndum Opinion"	Application Number 09/899,026 Filing Date July 6, 2001 First Named Inventor Stamm Art Unit 1615 Examiner Name Sheikh Attorney Docket Number 224407 NON PATENT LITERATURE DOCUMENTS of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of , magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Im Opinion" by District Judge Jordan dated 5-6-2005 in Abbott et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ. In Support of Motion for Summary Judgment" by Teva filed on 12-23-2004 in ories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. In Support of Motion for Summary Judgment" by Teva filed on 12-10-2004 in tories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. In Opinion" by District Judge Jordan dated 5-6-2005 in Abbott et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. In Opinion" by District Judge Jordan dated 5-6-2005 in Abbott et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. In Opinion" by District Judge Jordan dated 5-6-2005 in Abbott et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. In Opinion" by District Judge Jordan dated 5-6-2005 in Abbott et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. In Opinion Patent No. 1 273 293 filed on 9-2-2005 by (French Language Document). In Support of Motion filed on 9-23-2005. (English Language Translations). In Sarael Patent No. 130790 filed 5-4-2005 by Teva; and Remarks in Opposition filed on 9-23-2005. (English Language Translations). Atherosclerosis, 110(Suppl.):S45-S48 (1994).		
9/8	12	"Oper Abbot	ning E	Brief in Support of oratories et al v. T	Motion for Summary Judg Feva Pharmaceuticals USA	ment" by Teva filed on 12-23-2004 in A, Inc., Delaware, CA No. 02-1512.		
		13	"Oper Abbot	Application Number 09/899,026 Filing Date July 6, 2001 First Named Inventor Stamm Art Unit 1615 Examiner Name Sheikh Attorney Docket Number 224407 NON PATENT LITERATURE DOCUMENTS ude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of title (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. morandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott paratories et al v. Impax Laboratories, Inc., Delaware, CA No. 03-120-KAJ. ning Brief in Support of Motion for Summary Judgment" by Teva filed on 12-23-2004 in the taboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Inning Brief in Support of Motion for Summary Judgment" by Teva filed on 12-10-2004 in the taboratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion" by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva Pharmaceuticals USA, Inc., Delaware, CA No. 02-1512. Innorandum Opinion by District Judge Jordan dated 5-6-2005 in Abbott oratories et al v. Teva				
		14	"Men	norar rator	ndum Opinion" b ies et al v. Teva	oy District Judge Jordan Pharmaceuticals USA,	to a collection of information unless it contains a valid OMB control number. Complete if Known Umber 09/899,026 July 6, 2001 Inventor Stamm 1615 If Sheikh Sheikh Stet Number 224407 URE DOCUMENTS TERS), title of the article (when appropriate), title of posium, catalog, etc.), date, page(s), volume-issue and/or country where published. Indige Jordan dated 5-6-2005 in Abbott les, Inc., Delaware, CA No. 03-120-KAJ. Inmary Judgment" by Teva filed on 12-23-2004 in uticals USA, Inc., Delaware, CA No. 02-1512. Imary Judgment" by Teva filed on 12-10-2004 in uticals USA, Inc., Delaware, CA No. 02-1512. In 273 293 filed on 9-2-2005 by ument). Suppl.):S45-S48 (1994).	
. :		15					93 filed on 9-2-2005 by	aumber.
		16	Oppo Resp	ositio onse	n to Israel Pater to Opposition f	nt No. 130790 filed 5-4- filed on 9-23-2005. (Eng	2005 by Teva; and Remarks in lish Language Translations).	•
	Munoz et al, Atheroscle				t al, Atheroscle	erosis, 110(Suppl.):S	45-S48 (1994).	
	1,4	18	Phar	rmac page	ceutical Pelletizes 1-13; 160-16	zation Technology, M 61; and 234-235 (198	arcel Dekker, Inc., Volume 9).	

•	/		
Examiner Signature	mesa M. Sho Elle	Date Considered	12/09/05

Modern Pharmaceutics, Third Edition, Marcel Dekker, Inc., pages 131-133

Pharmaceutical Dosage Forms, Tablets, Second Edition, Marcel Dekker, Inc.,

pages 5-28; 88-107; 133; 142; 160-165; and 260-267 (1989).

19

20

and 335-336 (1996).

^{*}EXAMINER: Initial if refigence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

			ct of 1995, no persons ar	e required to respond to a collection	n of information unless it contains a valid OMB control number. Complete if Known
Substitu	Substitute for form 1449/PTO			Application Number	09/899,026
INF	ORMATIO	N DIS	CLOSURE	Filing Date	July 6, 2001
STA	STATEMENT BY APPLICANT			First Named Inventor	Stamm
	FORMATION DISCLOSUR ATEMENT BY APPLICAN (Use as many sheets as necessary)			Art Unit	1615
	(Use as many sheets as necessary)			Examiner Name	Sheikh
Sheet	3	of	4	Attorney Docket Number	224407

	Examiner nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	Т
5 <u>L</u>	PE		number(s), publisher, city and/or country where published.	
) \$\ T.	48 % 6 7005	21	Shepherd, Atherosclerosis, 110(Suppl.):S55-S63 (1994).	
7740	AS OF	22	Adkins et al, Drugs, 54(4):615-633 (October 1997).	
	9/8	23	Letter from Teva/Novopharm to Fournier Pharma Inc. regarding Invalidity and Ambiguity of Canadian Patent Nos. 2,219,475 and 2,372,576 (pages 1-15) (September 19, 2005).	
				L
		. :		
	· :	,		
			· ·	
		<u> </u>		

Examiner Signature	Ohumera & Breigh	Date Considered	12/09/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2060. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Peperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Co.	mpiete if Known	`
Application Number	09/899,026	
Filing Date	July 6, 2001	
First Named Inventor	Stamm	
Art Unit	1615	
Examiner Name	Sheikh	
Attorney Docket Number	224407	
	Application Number Filing Date First Named Inventor Art Unit Examiner Name	Filing Date July 6, 2001 First Named Inventor Stamm Art Unit 1615 Examiner Name Sheikh

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.	Number-Kind Code ^{2 (# known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
18 40	24	^{US-} 6,027,747	02-22-2000	Terracol et al	
//1 ⁶⁴	25	^{US-} 5,633,015	05-27-1997	Gilis et al	
6 12005	26	^{US-} 5,145,684	09-08-1992	Liversidge et al	
	/27	^{US-} 4,629,624	12-16-1986	Grouiller et al	
DEMARK		US-			
OEMO	_	US-			
		US-			
	. , .	US-			
		US-			
· .	: . ·	US-	 		
		US-	1.		
		US-			
		US-	-		

OCT

		FORE	IGN PATENT DOCU	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	76
6		Country Code ³ Number ⁴ Kind Code ⁵ (If known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	28	CA 2,142,848	03-17-1994	Janssen Pharmaceutica		
7	29	CA 960,670	01-07-1975	Orchimed SA		
	30	WO 98/31360	07-23-1998	Pharma Pass		┖
	31	WO 97/12581	04-10-1997	Pharma Pass		
10	32	CA 2,219,475	07-09-2002	Laboratoires Fournier, SA		L
40	33	CA 2,372,576	02-10-2004	Laboratoires Fournier, SA		

Examiner Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as Indicated on the document under WiPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.